** Shares of vaccine maker Novavax NVAX.O rise 28.9% to $7.67 premarket
** Co swings to Q1 profit from a year-ago loss, helped by reduced costs related to the development and sale of its COVID-19 vaccines
** Says discussions with the US FDA regarding its proposed study design for its COVID-19 vaccine are ongoing
** Reports Q1 net income came of $519 million, compared to a net loss of $148 million a year earlier
** Reports quarterly revenue of $667 million up from $94 million a year ago, and beating analysts' estimate of $343.85 million, as per data compiled by LSEG
** Last month, the U.S. health regulator asked Novavax to produce more data on its COVID-19 vaccine if it gets full approval
** Up to last close, NVAX down 26% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.